This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-4630v1 69/13/5331    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Røsland, G. V. Articles by Schichor, C. PubMed PubMed Citation Articles by Røsland, G. V. Articles by Schichor, C.

Long-term Cultures of Bone Marrow–Derived Human Mesenchymal Stem Cells Frequently Undergo Spontaneous Malignant Transformation

Department of ¹ Biomedicine, ² Hematology Section, Department of Medicine, ³ Section of Pathology, The Gade Institute, and ⁴ Section of Oncology, Institute of Medicine, University of Bergen; Departments of ⁵ Pathology and ⁶ Oncology, Haukeland University Hospital, Bergen, Norway; ⁷ Neuro-oncological Laboratory, Department of Neurosurgery, Ludwigs-Maximilians-University; ⁸ Institute for Molecular Immunology, National Research Center for Environment and Health, Munich, Germany; and ⁹ NorLux Neuro-Oncology, Centre Recherche de Public Santé, Luxembourg

Requests for reprints: Rolf Bjerkvig, Department of Biomedicine, University of Bergen, Jonas Lies vei 91, N-5009 Bergen, Norway. Phone: 47-55-58-63-52; Fax: 47-55-58-63-60; E-mail: rolf.bjerkvig{at}biomed.uib.no.

Key Words: hMSC • TMC • malignant transformation • biosafety • tumorigenesis

Human mesenchymal stem cells (hMSC) aid in tissue maintenance and repair by differentiating into specialized cell types. Due to this ability, hMSC are currently being evaluated for cell-based therapies of tissue injury and degenerative diseases. However, extensive expansion ex vivo is a prerequisite to obtain the cell numbers required for human cell-based therapy protocols. Recent studies indicate that hMSC may contribute to cancer development and progression either by acting as cancer-initiating cells or through interactions with stromal elements. If spontaneous transformation ex vivo occurs, this may jeopardize the use of hMSC as therapeutic tools. Whereas murine MSC readily undergo spontaneous transformation, there are conflicting reports about spontaneous transformation of hMSC. We have addressed this controversy in a two-center study by growing bone marrow–derived hMSC in long-term cultures (5–106 weeks). We report for the first time spontaneous malignant transformation to occur in 45.8% (11 of 24) of these cultures. In comparison with hMSC, the transformed mesenchymal cells (TMC) showed a significantly increased proliferation rate and altered morphology and phenotype. In contrast to hMSC, TMC grew well in soft agar assays and were unable to undergo complete differentiation. Importantly, TMC were highly tumorigenic, causing multiple fast-growing lung deposits when injected into immunodeficient mice. We conclude that spontaneous malignant transformation may represent a biohazard in long-term ex vivo expansion of hMSC. On the other hand, this spontaneous transformation process may represent a unique model for studying molecular pathways initiating malignant transformation of hMSC. [Cancer Res 2009;69(13):5331–9]